Washington, DC — The Select Investigative Panel has issued subpoenas to two financial entities — Scinto Group, LLP and Five Star Bancorp — in an effort to obtain StemExpress accounting and banking records, which the fetal tissue procurement business has failed to produce pursuant to previous subpoenas.
At a hearing held on April 20, 2016, on The Pricing of Fetal Tissue, the consensus among witnesses was that a full review of accounting documents by the Select Investigative Panel was warranted in order to determine whether or not StemExpress profited from the sale of human fetal tissue.
“In light of the advice we received from witnesses at our hearing last month, these subpoenas are necessary in order for the Select Investigative Panel to complete a full review of StemExpress’ accounting records,” Chairman Blackburn said. “Documents uncovered by our investigation so far point to the very troubling possibility that StemExpress may have violated federal law by profiting from the sale of baby body parts. We have learned that not only is this investigation warranted, but further examination of accounting records is needed to get the complete facts about what was actually going on.”
Click here to read the subpoena that was sent to Scinto Group, LLP, and here to read the subpoena sent to Five Star Bancorp.